Last reviewed · How we verify
GR1803
GR1803 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses.
GR1803 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced solid tumors (Phase 3 development).
At a glance
| Generic name | GR1803 |
|---|---|
| Sponsor | Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
GR1803 functions as a bispecific antibody designed to target multiple immune regulatory pathways simultaneously, thereby overcoming tumor immune evasion mechanisms. By engaging dual checkpoint targets, the drug aims to synergistically enhance T cell activation and proliferation while reducing immunosuppressive signals in the tumor microenvironment.
Approved indications
- Advanced solid tumors (Phase 3 development)
Common side effects
Key clinical trials
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
- A Study of GR1803 in Systemic Lupus Erythematosus (PHASE1, PHASE2)
- Phase I Trial of GR1803 Injection in Patients With RRMM (PHASE1, PHASE2)
- A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma (PHASE1, PHASE2)
- GR1803 Injection in Patients With RRMM (PHASE2)
- GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GR1803 CI brief — competitive landscape report
- GR1803 updates RSS · CI watch RSS
- Genrix (Shanghai) Biopharmaceutical Co., Ltd. portfolio CI